SCRI

SCRI offers: Robust clinical trial menus in multiple myeloma, leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms and various blood disorders • 100+ enrolled patients each year across the following hematology indications: - Leukemia - Lymphoma - Multiple Myeloma • 5 FACT/JACIE accredited HCT centers actively involved in research Immune Effector Cell Therapy (IECT) • 800+ patients have received FDA-approved or research CAR T-cell therapy to date within the network • 100+ IECT patients enrolled on a clinical trial in the past year • IECT treated diseases within SCRI: AML/MDS, sarcoma, melanoma, NSCLC, autoimmune, glioblastoma, gene therapy for sickle cell disease, multiple myeloma, DLBCL/ iNHL, B-Cell NHL/Mantle Cell, ALL/CLL/SLL Hematopoietic Cell Therapy (HCT) • Sarah Cannon Transplant & Cellular Therapy Network, within the SCRI family, is one of the world's largest providers of HCT, treating ~ 1,600 transplant and cellular therapy patients each year • Phase I-III auto and allo HCT experience Disease committees by indication allow SCRI network physicians to work collaboratively to advance blood cancer therapies. SCRI garners key opinion leaders in hematology and oncology who are highly engaged in cutting-edge research to consider any new trial opportunity offered to our network – allowing for strategic placement at SCRI sites best suited for optimal success. Where the Science of Collaboration Leads to Research Innovation. Our research network reaches 1 in 5 patients with cancer through our affiliated sites. How We're Advancing Therapies for People Facing Blood Cancer. 1,300+ Physicians who are providing access to clinical trials. 4,500+ Registered patients participating in clinical trials annually. 1,000+ Trials actively enrolling patients. 250+ Locations across the U.S. SCRI.com Transplant & Cellular Therapy / Complex Hematology Research Sites Early Phase Sites Multi-phase Research Sites Cell Therapy Sites RGB_SCRI Heme Research Presence Map_Version 1.1 Transplant & Cellular Therapy / Complex Hematology Research Sites Early Phase Sites Multi-phase Research Sites Cell Therapy Sites RGB_SCRI Heme Research Presence Map_Version 1.1 SCRI Hematology Research Presence Transplant & Cellular Therapy / Complex Hematology Research Sites Early Phase Sites Multi-phase Research Sites Cell Therapy Sites Transplant & Cellular Therapy / Complex Hematology Research Sites Early Phase Sites Multi-phase Research Sites Cell Therapy Sites RGB_SCRI Heme Research Presence Map_Version 1.1 Learn more SCRI's capabilities, career opportunities, and presence at ASH As a leader in drug development, SCRI has conducted 800+ first-in-human trials to date.

• Cover